Avidity begins Cohort C enrollment in FORTITUDE trial Avidity Biosciences has begun enrollment of Cohort C of the Phase 1/2 FORTITUDE™ clinical trial. Below is Avidity’s letter to the FSHD… Read More »
Avidity begins Cohort C enrollment in FORTITUDE trial
Aging in place – Tips for planning ahead
Notes by Helen Cave on behalf of the Wellness Hour Life brings change. Life would be boring if it didn’t encompass change. Yet the changes that FSHD brings to us… Read More »
A note to our families from CEO Mark Stone
A note to our families This morning, Fulcrum released top-line results of its phase 3 trial for Losmapimod. The results showed no difference between placebo and active ingredient groups. Therefore,… Read More »
Why put off getting hearing aids?
They’re now more affordable and available by Richard Holmes, Sandwich, Massachusetts If you’re straining to hear what people say, or find yourself cranking up the volume on your TV to… Read More »
Advocating for Change on Capitol Hill
A Day of Impact in Washington, D.C. On May 8th, the FSHD Society held its first-ever Day on Capitol Hill in Washington, D.C. This milestone in our advocacy efforts brought… Read More »